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ABSTRACT

ACTIVITY ANALYSIS OF THE FRAGILE X MENTAL RETARDATION PROTEIN
ISOFORMS 1, 2 AND 3: RECOMBINANT BACTERIAL EXPRESSION AND
PURIFICATION WITH SUBSEQUENT QUANTITATIVE ANALYSIS OF BINDING
TO IN VIVO TARGET G-QUADRUPLEX FORMING RIBONUCLEIC ACIDS AND
REGULATION OF TRANSLATION
By
Timothy L. Evans
August 2010

Dissertation supervised by Dr. Mihaela-Rita Mihailescu
The loss of expression of the fragile X mental retardation protein (FMRP) leads to
fragile X syndrome.

Fragile X syndrome is the most prevalent inheritable mental

retardation. FMRP has two types of RNA binding domains, two K-homology domains
and an arginine-glycine-glycine box domain, and is proposed to act as a translation
regulator of specific mRNA. Despite extensive research, the mechanism by which FMRP
loss leads to the fragile X syndrome remains unclear. Thus, there is high interest to
produce sufficient quantities of pure recombinant FMRP for biochemical and biophysical
studies of the protein function. However, the recombinant bacterial expression of FMRP
has had limited success, and subsequent recombinant eukaryotic and in vitro systems may
produce FMRP which is posttranslationally modified, as phosphorylation and arginine
methylation have been shown to occur on FMRP. In this study, we have successfully
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isolated the conditions for recombinant expression, purification and dialysis of full-length
FMRP using Escherichia coli, with a high yield. The expression of FMRP using E. coli
renders the protein devoid of the posttranslational modifications of phosphorylation and
arginine methylation, allowing for the further study of the direct effects of these
modifications individually and simultaneously. Additionally, FMRP has been shown to
undergo alternative splicing, with one of the splicing sites in close proximity to the
FMRP domain shown to be involved in binding G quadruplex mRNA with high affinity
and specificity. We have analyzed how naturally occurring truncations in the FMRP
sequence affect its RNA binding affinity, by applying the expression, purification and
dialysis process to the second and third longest FMRP isoforms, followed by subsequent
analysis of the G quadruplex mRNA binding properties by fluorescence spectroscopy.
Our results show that as FMRP gets truncated by alternative splicing, its mRNA binding
affinity increases. To test a model we proposed for FMRP translation regulation activity,
we developed a luciferase reporter gene construct that contains the G quadruplex
structure in the mRNA 5’-untranslated region. Using luminescence spectroscopy to
analyze luciferase translation, we showed that low levels of full-length FMRP reduces
luciferase translation, and as the concentration of full-length FMRP increases the
luciferase translation increases.
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CHAPTER 1: INTRODUCTION

1.1

Fragile X Syndrome: Background and History
The connection between sex-linked inheritance and mental retardation was first

shown in 1943 and, in 1969, patients afflicted with this disorder were shown to have an
abnormal X chromosome structure which was designated as the fragile X chromosome
[1, 2]. In 1991, the fragile X mental retardation gene (FMR1) was discovered and it was
shown that a gene mutation, specifically an unstable trinucleotide repeat expansion,
occurred in patients diagnosed with fragile X syndrome (FXS) [3]. FXS is the most
prevalent inheritable mental retardation in humans, affecting approximately one in 4000
males and one in 8000 females [4]. Patients diagnosed with FXS exhibit phenotypic IQ
scores of 20 to 60, hyperactivity, avoidance of eye contact, and about 30% also have
autism [5]. In addition to the cognitive defects, FXS patients have increased head-size,
elongated face, protruding ears, and males experience macro-orchidism.

1.2

Fragile X Syndrome: Molecular Diagnosis and Gene Mutation
The FXS phenotype is caused by the loss of expression of the fragile X mental

retardation protein (FMRP) [6-8], whose transcriptional silencing is caused by an
expansion of greater than 200 cytosine-guanine-guanine (CGG) repeats in the 5’untranslated region (UTR) of the FMR1 gene [5, 7, 8]. The cytosines of this region of
CGG repeats, along with an upstream CpG island, become hyper-methylated.

The

combined effects of the trinucleotide repeat expansion and hyper-methylation events are
thought to directly block binding of transcription factors and/or to cause chromatin
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Figure 1. Model of FMRP function in the neuron. FMRP is transported into the nucleus of
neurons via its nuclear localization signal (1). Once in the nucleus FMRP associates with
cellular mRNAs as well as a number of proteins to form a large ribonucleoprotein complex
(mRNP) (2) that is subsequently transported out of the nucleus via the nuclear export
signal of FMRP (3). Once in the cytoplasm the FMRP mRNP can either associate with
ribosomes in the cell body (4) producing proteins (5) that can be transported into the axon
(6) or dendrites (7), or the FMRP mRNP can itself be transported into the dendrites (8)
and associate with ribosomes to produce proteins in response to metabotropic glutamate
receptor (mGluR) activation (10). Both the local translation of proteins in the dendrite and
transport of proteins from the cell body mediate synaptic plasticity and spine maturation
(11). Adapted from [8].
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condensation, which in turn blocks the binding of transcription factors.

Since the

discovery that the FMRP transcription loss leads to FXS, much effort has been put forth
in the study of FMRP; however, the function of the protein, the role it plays in the brain,
and how its loss leads to mental retardation have not been fully elucidated.

1.3

Fragile X Mental Retardation Protein
FMRP is found primarily in the neurons and testes and it is thought that FMRP

acts a regulator of gene expression at the level of translation. The proposed role of
FMRP is to bind specific target messenger RNAs (mRNAs), transport those mRNAs
throughout the cell, and regulate their translation in response to synaptic input (Fig 1) [8].
FMRP contains two different RNA binding domains, the arginine-glycine-glycine
box (RGG box) domain and two K-homology (KH) domains, KH1 and KH2 (Fig 2A)
[8]. FMRP also has a nuclear localization signal (NLS), as well as a nuclear export signal
(NES) [8]. Additionally, FMRP has been shown to undergo the posttranslational
modifications of phosphorylation and arginine methylation [9, 10].

A

NLS

KH1

KH2 NES

RGG

B
RRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSR
Figure 2. (A) Schematic of full-length FMRP showing the nuclear
localization signal (NLS) in blue, the K-homology domains (KH1,
KH2) in pink and light green respectively, the nuclear export signal
(NES) in red, and the RGG box domain (RGG) in green. (B)
Sequence of the FMRP RGG box domain showing the RGG
repeats underlined and bolded. Adapted from [4].
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The presence of both the NLS and the NES led to the proposal that, through these
localization signals, FMRP shuttles between the nucleus and cytoplasm, hence, acting to
transport a subset of mRNAs from the nucleus to the distant sites in the cell (Fig 1) [11].
FMRP has indeed been detected in both the cytoplasm and, in smaller quantities, the
nucleus [11-13]. It has been proposed that nascent FMRP is part of polyribosomal
complexes in the cytoplasm and that normal dissociation from the polyribosomes along
with the presence of the NLS enables FMRP to be transported into the nucleus. Then, in
response to growth stimuli, FMRP is transported into the nucleus where it binds its target
mRNAs. The subsequent transport back to the cytoplasm is exportin 1-dependent and the
FMRP-mRNA complex once again associates with ribosomes.
The RGG box, found in select RNA binding proteins, was first described in 1991
(Fig 2B) [14]. There is no consensus sequence for this domain and the RGG box was
originally defined as having two or more RGG repeats interspersed with other,
particularly aromatic, residues. More recent bioinformatic analysis with parameters of
two or three RGG repeats, having five to nine residues separating the repeats, identified
44 human proteins that contain RGG boxes [15]. This indicates both the variability of the
RGG box domain sequences and, based on the number of proteins found, the biological
relevance of the RGG box. Proteins containing the RGG box domain also typically
contain other RNA binding domains, for example FMRP contains two KH domains and
the RGG box domain. One possible explanation is that the mRNA targets of RGG box
containing proteins vary, thus, the RGG box could act in tandem or synergistically with
the other RNA binding domains during the mRNA binding process. Alternately, the
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multiple different RNA binding domains contained within a given protein could act
independent of one another and target different RNAs.
Biochemical studies have shown that the RGG box of FMRP targets and binds
certain guanine-rich mRNA sequences that fold into the G quadruplex secondary
structure (Fig 3) [4, 6, 16, 17]. Formed from four guanine residues, a G quartet has a
planar conformation stabilized by Hoogsteen base pairing and a central K+ ion (Fig 3A)
[4, 18]. Several planar G quartets stack to form G quadruplex structures (Fig 3B). It is
thought that the RGG box domain is dynamic and unstructured, becoming structured
upon binding of G quadruplex mRNA.

A

N

N
H

N
N

N
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O

H
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H
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R
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N
N

N

N

K+

H

N

H

N

H
H

B

H

R

H

N
H

H
N

N
R

Figure 3. (A) Hydrogen bonding and orientation of guanines for the Hoogsteen base
pairing of a K+ dependent G quartet. (B) Stacked planar G quartets stabilized by K+ ions
to form an example of an intermolecular G quadruplex (PDB: 2gwe).

In addition to the RGG box, FMRP possesses two separate KH domains (Fig 2A).
The KH domain, first identified and named from the human heterogeneous nuclear
ribonucleoprotein K, consists of approximately 70 residues, is involved in a myriad of
5

processes such as mRNA splicing or transcriptional regulation, and is found in a diverse
variety of proteins in archaea, prokaryotes and eukaryotes [19]. The typical function of
the KH domain is RNA and single-stranded DNA recognition, and the domain is
typically found in multiple copies within the same protein. It has been shown that FMRP
uses its KH2 domain to bind to RNAs which form the kissing-loop secondary structure
[20]. The kissing-loop structure is a stable complex formed by Watson-Crick basepairing between the loops of two RNA hairpins. The kissing-loop structure is highly
dependent on divalent cations and is found in prokaryotes, eukaryotes and viruses [21].
Recent studies have revealed a novel mechanism to regulate gene expression at
the level of translation, which is proposed to involve the G quadruplex mRNA secondary
structure (Fig 3B) [22]. However, the full extent of the mRNA G quadruplex biological
activity is not well understood, and the role it plays in translation regulation, or any other
processes, have not been fully elucidated. Biophysical studies have shown that both
DNA and RNA containing specific guanine-rich sequences can fold into G quadruplexes.
DNA G quadruplexes became of special interest in the past decade as it was discovered
that they are dispersed in eukaryotic genomes, being abundant in regions of biological
significance such as the telomeres and the promoters of many important genes [23].
There are, however, fewer examples of RNA G quadruplexes, which have been proposed
to be involved in transcription regulation, translation regulation, and in interacting with
prion proteins [24]. It is known that the genetic information governing translation is
localized mainly to the 5’- and 3’-UTR of mRNA and that it may involve both the
sequence and secondary structure of these non-protein coding regions [22].
Bioinformatic analysis has found that 2334 and 3530 G quadruplexes could potentially
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exist in the 5’- and 3’-UTRs, respectively, of human mRNA transcripts from known
protein-coding genes. Furthermore, the role of the G quadruplex mRNA secondary
structure as a mode of posttranscriptional regulation has been confirmed by showing that
the individual introduction of known G quadruplexes from the 5’-UTRs of two different
mRNAs into the mRNA 5’-UTR of a reporter gene which resulted in the translation
inhibition of the reporter gene [25, 26]. The mRNA G quadruplex structure shows
promise as a mechanism the cell uses to control gene expression at the level of
translation, and the fact that it is recognized and bound by the RGG box domain of
FMRP is of high interest. Additionally, a patient recently diagnosed with FXS showed
normal levels of FMRP (Dr. Bassem Hassan, Katholieke Universiteit Leuven,
unpublished data). Genetic analysis showed a frameshift mutation that occurs between
the RGG repeats of the RGG box domain, thereby abolishing over half the RGG box
domain and eliminating the second RGG repeat, truncating the C-terminus of FMRP, and
changing the identity of the residues that remained after the mutation site.

The

elimination of a functional RGG box domain for this patient, which expresses normal
levels of mutated FMRP, illustrates the importance of this domain for the function of
FMRP.
The mRNA product of the FMR1 gene has been shown the undergo alternative
splicing that involves exons 12 and 14 and the choice of acceptor sites in exons 15 and 17
[27-30]. These splicing patterns could potentially form 20 different isoforms, however so
far only five different isoforms have been detected in various tissues (Fig 4) [27, 28, 31,
32]. Neither the relative levels of expression, nor the prevalent distributions of the
various exon splicing products are known [33]. This study focuses on the three longest
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FMRP
Isoform
1
2
3
4
5

15a
Exons 1-11

Exon 12

Exons 1-11

8

Exon 12

Exons 1-11

Exon 13

Exons 1-11

15
16
17
18
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20

Exon 14

Exon 13

Exons 1-11

Exon 13

Exons 1-11
Exons 1-11

Exon 12 Exon 13

Exons 1-11

Exon 12 Exon 13

Exons 1-11

Exon 14

Exon 13
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Figure 4. Schematic of the 20 possible FMRP isoforms resultant from alternative
splicing of the FMR1 mRNA. The three exon 15 splice acceptor sites are 15a, 15b and
15c. The two exon 17 splice acceptor sites are 17a and 17b. The FMRP isoforms
expressed in this study, ISO1, ISO2 and ISO3, vary based on the three exon 15 acceptor
sites. Specifically, ISO1 utilizes splice acceptor site 15a, while ISO2 and ISO3 utilize
sites 15b and 15c, respectively. ISO4, ISO5 and ISO6 are identical to ISO1, ISO2 and
ISO3, respectively, but lack exon 14. ISO7, ISO8 and ISO9 are identical to ISO1, ISO2
and ISO3, respectively, but lack exon 12. ISO10, ISO11 and ISO12 are identical to ISO1,
ISO2 and ISO3, respectively, but lack both exons 12 and 14. ISO13, ISO14 and ISO15
are identical to ISO1, ISO2 and ISO3, respectively, except utilize splice acceptor site 17b.
ISO16 is identical to ISO15 but lacks exon 14. ISO17, ISO18 and ISO19 are identical to
ISO7, ISO8 and ISO9, respectively, except utilize splice acceptor site 17b. ISO20 is
identical to ISO15 but lacks exons 12 and 14. Adapted from [13].
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FMRP protein products, isoform 1, 2 and 3 (ISO1, ISO2 and ISO3 respectively) (Fig 5).
The immature FMR1 transcript contains 17 exons, and the ISO2 and ISO3 products result
from the three alternate splice acceptor sites at exon 15. ISO1, representing the longest
expressed FMRP isoform, is truncated by 13 residues to form ISO2 and another 12
residues to form ISO3. All three FMRP isoforms maintain the NLS, KH1, KH2, NES
and RGG box domains. The splice formation of ISO2 and ISO3 does result in the loss of
the residues shown to be posttranslationally phosphorylated. The interest in these three
FMRP isoforms stems, in part, from the fact that these truncations are in upstream close
proximity to the RGG box. As stated previously, it is thought that the region surrounding
and including the RGG box is predominately unstructured, hence the intent to elucidate
the effects of these naturally occurring truncations in this dynamic region on the FMRP
RGG box ability to bind G quadruplex mRNAs.
Mammalian FMRP was found to be phosphorylated in a region located Nterminal and in the close proximity, to the RGG box domain (Fig 5) [9, 34]. It has been
shown that unphosphorylated FMRP associates with actively translating polyribosomes,
while phosphorylated FMRP associates with stalled polyribosomes, suggesting that this
posttranslational modification modulates the FMRP translation regulator function [35].
The two enzymes implicated in the phosphorylation and dephosphorylation of FMRP
were identified as the ribosomal protein S6 kinase and the protein phosphatase 2A,
respectively [36, 37]. It has been proposed that FMRP phosphorylation is coupled to
translation repression, whereas FMRP dephosphorylation signals the release of the target
mRNAs for translation [36-38].

In addition, it has been proposed that the

phosphorylation state of FMRP determines its inclusion with the microRNA pathway by
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regulating its association with Dicer and Dicer-containing complexes [34].

It is,

however, unclear if these phosphorylation and dephosphorylation events regulate the
FMRP translation regulation activity by affecting its binding properties for G quadruplex
forming mRNA, or its interactions with other protein partners.

NLS

KH1

KH2 NES

RGG

↓
↓
↓ ↓
‡
‡
‡
TNSEASNASETESDHRDELSDWSIAPTEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSR
ISO1
DHRDELSDWSIAPTEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSR

ISO2
PTEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSR

ISO3
RRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSR

RGG Box Peptide
Figure 5. The protein sequence truncation products from the alternative splice acceptor
sites at exon 15 of FMR1 mRNA. ISO1 is truncated by 13 residues to form ISO2,
truncated another 12 residues to form ISO3. The RGG repeats comprised in the RGG
box domain are underlined and bolded. The sites of posttranslational phosphorylation are
indicated by double daggers (‡). The region of phosphorylation is lost upon forming ISO2
and ISO3. The sites or posttranslational arginine methylation are indicated by arrows (↓).
The sequence of the 32mer synthetic RGG box peptide, and consequently the RGG box
domain sequence, is also shown. Adapted from [8, 34, 39].

It has also been shown that FMRP is posttranslationally methylated within its
RGG box and that its binding affinity for homoribopolymers (poly(rG), poly (rC), poly
(rA), or poly (rU)) changes when the protein is produced in the presence of protein
arginine methyltransferases (PRMTs) (Fig 5) [10, 39-41]. The PRMT responsible for
methylation is not known, but FMRP is asymmetrically dimethylated indicating that a
type I methyltransferase is responsible [40].
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It has been proposed that PRMT1 is

responsible for methylating FMRP since this enzyme is responsible for more than 90% of
the type I arginine methylation activity in cells, and can methylate peptides containing
multiple glycine-arginine-glycine sequences in vitro as well as proteins containing
multiple glycine-arginine-glycine sequences in vivo. It is noteworthy that of the four
arginines identified as being asymmetrically dimethylated, two reside on the RGG repeats
comprised in the RGG box domain, whereas the other two are the only arginines that
reside between these RGG repeats. Moreover, methylation of FMRP reduced its ability
to associate with Sc1, a G quadruplex forming synthetic RNA [10]. These results suggest
that protein arginine methylation plays an important role in defining the interactions of
FMRP with its G quadruplex forming mRNA targets.

1.4

In vivo Ribonucleic Acid Targets of the FMRP RGG Box
Several in vivo neuronal G quadruplex forming mRNA FMRP targets have been

identified, such as the microtubule associated protein 1B (MAP1B) mRNA and
semaphorin 3F (S3F) mRNA [4, 6, 17, 31, 42, 43]. In addition, the FMRP mRNA has
also been proposed to form a G quadruplex structure which has been shown to be
recognized by FMRP [44], leading to the proposal that FMRP could mediate its own
translation regulation. However recent evidence shows that FMRP does not regulate its
own mRNA translation, but rather its binding to its own mRNA via a G quadruplex
structure plays a role in the alternative splicing of this RNA [44]. The MAP1B mRNA,
which interacts with FMRP in vivo, has been shown to form a G quadruplex structure
which is bound by the FMRP RGG box peptide in vitro with high affinity and specificity
[4, 45-48]. Regulation of MAP1B mRNA translation is of great importance since its
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protein product has been shown to be involved in modulating microtubule dynamics,
neurite extension and synapse development [4]. S3F mRNA, which has also been shown
to interact with FMRP in vivo, forms a G quadruplex structure as well, which is bound by
the FMRP RGG box peptide in vitro with high affinity and specificity [6, 17, 45, 47].
S3F mRNA is an important target of FMRP since the protein it encodes, Sema 3F, plays
an important role in brain development by functioning as a chemo-repellant to axon
extension, neuronal migration, and the guidance of growth cones [17, 49, 50].

1.5

Model for FMRP Translation Regulator Function
Increasing the ratio of FMRP RGG box peptide to mRNA has been shown by

circular dichroism (CD) spectroscopy to result in the unwinding of the RNA G
quadruplex structure of both MAP1B mRNA and S3F mRNA [4, 6, 17]. In addition,
identical results occurred when using the G quadruplex forming synthetic Sc1 RNA [16].
Though FMRP is mainly found in the cytoplasm, it binds mRNAs in the nucleus and has
nucleo-cytoplasmic shuttle activity. In the cytoplasm, FMRP exhibits mRNA chaperone
activity, and it is believed to assist in the transport of its mRNAs targets to actively
translating ribosomes, leading to its postulated activity as a translational regulator of
mRNAs [51-53]. In addition, it has been shown that stimulation of the metabotropic
glutamate receptor 5 (mGluR5) on dendritic spines causes a rapid localized increase in
translation of FMR1 mRNA, hence an increase in the local concentration of FMRP [38,
54, 55]. The finding that this local protein synthesis was followed by a rapid decrease in
FMRP levels back to baseline suggests a dynamic regulation of the FMRP concentration
[55]. Based on these findings, Menon et al proposed the following model for FMRP
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A

FMRP

FMRP
FMRP
FMRP
FMRP

3’
5’

3’

5’
mGluR

mGluR
Agonist

C

D

3’
3’

5’

5’

C
N

mGluR

mGluR

Figure 6. (A) As stated in Section 1.3, FMRP has entered the nucleus using its NLS,
bound nascent G quadruplex mRNA as part of the mRNP, and transported this mRNA to
the cytoplasm using its NES. The FMRP has induced a state of repressed translation for
the G quadruplex mRNA and the molecular partners involved in the mRNP are not shown.
The mRNP complex, in in a state of repressed translation, is transported to a maturing
axon or dendrite (as shown). (B) Upon stimulation of the mGluR receptor by an agonist, a
rapid local increase in FMRP concentration occurs. (C) The excess FMRP has unwound
the G quadruplex structure of the target mRNA. (D) The unwound target mRNA is
translated to form nascent protein (blue) during neuronal maturation. Adapted from [4].

function (Fig 6) [4]: FMRP binds and stabilizes nascent target G quadruplex forming
mRNAs in the nucleus and, acting as a translation repressor, transports them in a
repressed state to distal sites in the cell. Upon the mGluR5 stimulation by an agonist,
there is a rapid increase in the local concentration of FMRP, which creates the high ratio
of FMRP to mRNA, and causes the unwinding of the mRNA G quadruplex structure.
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Once the G quadruplex structure of the target mRNA is unwound, the ribosome can then
proceed with translation.

1.6

Rationale for the Expression of Recombinant FMRP in Escherichia coli
Since the discovery of the FMR1 gene, many studies have attempted to employ

recombinant methods to express FMRP. Bacterial, eukaryotic and in vitro recombinant
expression systems have netted only satisfactory results, with problems involving low
levels of FMRP expression and yield, as well as protein precipitation [10, 13, 28, 29, 35,
43, 45, 56-65]. Furthermore, FMRP is known to undergo phosphorylation and arginine
methylation, and such posttranslational modifications might occur when using eukaryotic
and in vitro systems of expression, as the enzymes involved in these pathways are present
in such systems [9, 10, 34-41]. However, bacterial cells, such as Escherichia coli, do not
have the enzymes involved capable of these posttranslational modifications. Therefore, it
is of great interest to express recombinant FMRP using bacterial systems because it
renders it devoid of phosphorylation and arginine methylation. Producing FMRP devoid
of these modifications allows for investigation of the explicit effects of phosphorylation
and arginine methylation, individually and simultaneously.

1.7

Specific Aims of the Research
Specific Aim 1: Recombinant Expression in E. coli, Purification and Dialysis of
Fragile X Mental Retardation Protein Isoforms 1, 2 and 3.
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Specific Aim 2: Quantitative Analysis of Binding Activity of Fragile X Mental
Retardation Protein Isoforms 1, 2 and 3 to in vivo Neuronal Target G quadruplex
Forming Messenger Ribonucleic Acid.

Specific Aim 3: Analysis of Translation Regulation Activity of Fragile X Mental
Retardation Protein Isoforms 1, 2 and 3 for a Reporter Gene with a G quadruplex
Structure in the 5’-Untranslated Region.

1.8

Relevance of the Research
The research performed in this project will increase our understanding of the role

played by FMRP in neuronal development and how its absence leads to FXS. We have
developed the best protocol to date for the recombinant expression of the three longest
FMRP isoforms in E. coli, devoid of posttranslational modifications, with subsequent
purification, concentration and dialysis conditions. The fact that FMRP produced via our
developed method lacks phosphorylation and arginine methylation allows for
investigation of the explicit effects of these modifications, both individually and
simultaneously, on the various processes that FMRP is involved. We have demonstrated
that FMRP ISO1, ISO2 and ISO3 retain biological activity after undergoing the process
developed herein. Furthermore, we have shown that as FMRP ISO1 is truncated to form
ISO2 and ISO3, due to alternative splicing, the binding affinity becomes tighter for in
vivo neuronal target G quadruplex mRNA, indicating that neuronal cells utilize
alternative splicing as a means to regulate the biological activity of FMRP.
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CHAPTER 2: MATERIALS AND METHODS

2.1

Expression of Recombinant FMRP ISO1
The recombinant plasmid pET21a-FMRP, encoding ISO1 fused with a C-terminal

6x histidine affinity tag and an N-terminal T7 affinity tag, was a gift kindly provided by
Dr. Bernhard Laggerbauer [60]. The plasmid was transformed into Rosetta 2(DE3)
pLysS E. coli cells (Novagen), which were cultured at 37 °C, 250 rpm in Luria-Bertani
(LB; Fisher Scientific) media containing 200 μg/mL ampicillin (Amp; MP Biomedical)
and 15 μg/mL chloramphenicol (Chl; MP Biomedical) and subsequently mixed 1:1 with
ultra-pure glycerol and frozen at -80 °C. The concentrations of Amp and Chl were
maintained constant throughout cell culturing.
Cells were spread onto an LB + Amp + Chl agar plate using 4-way spread
technique and incubated 12 h at 37 °C. Single colonies were picked and cultured (culture
1) in 250 mL LB + Amp + Chl media in a 1 L flask at 37 °C, 250 rpm, 12 h. Eight 2 L
flasks (culture 2) were prepared with 500 mL LB + Amp + Chl and 25 mL culture 1 was
added to each flask, followed by incubation at 37 °C, 250 rpm until OD 600 reached 0.81.0. The expression of FMRP ISO1 was induced by adding isopropyl β-D-1thiogalactopyranoside (IPTG) to a final concentration of 1 mM to culture 2 which was
then transferred to a separate incubator at 25 °C, 250 rpm for 12 h.
The eight 500 mL culture 2 flasks were equally combined into six 1 L centrifuge
flasks and cells were pelleted at 5000 g, 4 °C, 10 min. Pellets were weighed and
transferred to individual 50 mL round-bottom polycarbonate centrifuge tubes (Nalgene).
A 1:1 mixture of B-PER Bacterial Protein Extraction Reagent (Thermo Scientific) and 2x
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lysis buffer (20 mM HEPES, pH 7.5, 600 mM LiCl, 10 mM β-mercaptoethanol, 40 mM
imidazole, 10% glycerol) was added at 10 mL buffer/g cells to each pellet, followed by
the re-suspension of the pellets by vortexing. Cells were incubated at -20 °C until further
purification.

2.2

Purification of Recombinant FMRP ISO1
Resuspended cell pellets were thawed in a 25 °C water bath and then incubated on

ice for 30 min to allow lysozyme action encoded by the pLysS cell line. Cells were then
sonicated (Branson Sonifier Cell Disruptor 185) three times at a power of 6 for 30 sec
with 2 min on ice between bursts. The crude lysate was then centrifuged at 40,000 g, 4
°C, 30 min. A 10 cm x 1.5 cm diameter column was loaded with 10 mL Ni-NTA
Superflow resin slurry (Qiagen) at 4 °C and equilibrated with 5 column volumes of
equilibration buffer 1 (10 mM HEPES, pH 8.0, 300 mM LiCl, 5 mM β-mercaptoethanol,
5% glycerol, 20 mM imidazole) at 2 mL/min using the BioRad BioLogic LP system. The
entire clarified crude supernatant was loaded onto the column at a flow rate of 0.5
mL/min, followed by washes performed at a rate of 2 mL/min: 5 column volumes of
equilibration buffer 1, 10 column volumes of equilibration buffer 2 (same components as
equilibration buffer 1 except at pH 7.0), and 10 column volumes of wash buffer 1 (10
mM HEPES, pH 7.5, 300 mM LiCl, 5 mM β-mercaptoethanol, 5% glycerol, 100 mM
imidazole). An additional wash step was performed, at a flow rate of 1 mL/min with
wash buffer 2 (10 mM HEPES, pH 7.5, 300 mM LiCl, 5 mM β-mercaptoethanol, 5%
glycerol, 250 mM imidazole). Pure FMRP ISO1 was eluted at a flow rate of 1 mL/min
with elution buffer (10 mM HEPES, pH 7.5, 300 mM LiCl, 5 mM β-mercaptoethanol,
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5% glycerol, 500 mM imidazole), collecting 15 3 mL fractions.

Immediately after

elution, ethylenediaminetetraacetic acid (EDTA) was added to each collected fraction to a
final concentration of 1 mM and the fractions were stored at 4 °C until dialysis. Fractions
from the elution were analyzed via 10% tris-glycine sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and visualized by Coomassie blue stain
to assure purity (Fig 7).

2.3

Concentration of Recombinant FMRP ISO1
The concentration protocol was adapted from [66]. A sterile 50 mL beaker was

pre-chilled on ice and elution fractions 5-8, containing the highest concentration of
FMRP ISO1, were pooled therein. Dialysis tubing of 3500 MWCO, 29.3 mm diameter
(Fisher Scientific) was washed in sterile dH 2 O and filled with polyethylene glycol 20,000
(J.T. Baker) such that the polyethylene glycol consumed approximately 30% of the
available inner volume to allow for expansion.

The filled tubing was immersed

completely into the beaker containing FMRP ISO1. After pooling FMRP ISO1, the
volume for concentrating was 12 mL and the protein was concentrated to a final volume
of approximately 3 mL.

2.4

Dialysis of Recombinant FMRP ISO1
For the purpose of the mRNA binding experiments that were monitored by

fluorescence spectroscopy, FMRP ISO1 had to be devoid of imidazole. All dialysis
buffers were prepared two days in advance of use, without adjusting the pH, and allowed
to equilibrate overnight at 4 °C. The pH adjustments occurred one day prior to use and
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allowed to finish equilibration over night at 4 °C. Dialysis tubing of 10,000 MWCO, 7.5
mm diameter (Spectra/Por) was washed with sterile dH 2 O and the concentrated FMRP
ISO1 was added. All dialysis buffers were, volume-wise, approximately 667:1 to FMRP
ISO1 and incubations in the respective dialysis buffer occurred for 12 h at 4 °C. Each
dialysis buffer (2L) contained 10 mM HEPES, pH 7.5, 300 mM LiCl, 5 mM βmercaptoethanol, 5% glycerol, 1 mM EDTA and variable imidazole concentrations, as
follows: the first dialysis buffer contained 200 mM imidazole, the second contained 100
mM imidazole, the third contained 50 mM imidazole and the fourth contained no
imidazole. After dialysis, the concentration of FMRP ISO1 was determined to be 50 μM
by absorbance at 280 nm using an extinction coefficient of 46370 M-1 cm-1 adapted from
[67, 68]. The purity and retention of the protein were analyzed by 10% tris-glycine SDSPAGE and visualized by Coomassie blue stain (Fig 8).

2.5

Mass Spectrometry Analysis of FMRP ISO1
The identity of FMRP ISO1 was confirmed using peptide mass fingerprinting

(Genomics and Proteomics Core Laboratories, University of Pittsburgh) (Table 1).
FMRP ISO1 from a 10% SDS-PAGE gel was excised and trypsin digested followed by
analysis via matrix-assisted laser desorption/ionization-time of flight-mass spectrometry
(MALDI-TOF-MS). The five MALDI-TOF-MS characterized amino acid sequences
matched that found in FMRP ISO1.
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2.6

Production of the pET-21a Plasmid Encoding ISO2 and ISO3
The pET-21a-FMRP plasmid, encoding ISO1 fused with a C-terminal 6x histidine

affinity tag and an N-terminal T7 affinity tag, was a gift provided by Dr. Bernhard
Laggerbauer [60]. The truncations of FMR1 cloned into pET-21a, which encodes ISO1,
to form the genes to express ISO2 and ISO3 were performed by GenScript and confirmed
by DNA sequencing. The affinity tags remained intact after the gene truncations. The
plasmids containing the genes encoding ISO2 and ISO3 were also restriction digested
with XhoI to confirm the changes in size corresponding to the truncations and analyzed
by 1% agarose gel electrophoresis and visualized by ethidium bromide stain (Fig 9).

2.7

Expression, Purification, and Dialysis of Recombinant FMRP ISO2 and ISO3
The pET-21a plasmids encoding ISO2 and ISO3 were transformed into Rosetta2

(DE3) pLysS E. coli cells. The protocol developed for the expression, purification,
concentration and dialysis of FMRP ISO1 was applied to ISO2 and ISO3. After dialysis,
the concentration of FMRP ISO2 and ISO3 were determined to be similar to that of ISO1
by absorbance at 280 nm using extinction coefficients of 46370 M-1 cm-1 and 40680 M-1
cm-1, respectively, adapted from [67, 68]. Successful production of pure, dialyzed FMRP
ISO2 and ISO3 was confirmed by 10% tris-glycine SDS-PAGE analysis and visualized
by Coomassie blue stain (Fig 10).
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2.8

Analysis of FMRP ISO1, ISO2 and ISO3 Binding Activity to G quadruplex

Forming mRNA
In order to ensure that FMRP ISO1 maintained mRNA binding activity after the
aforementioned processes, we performed a fluorescence RNA binding assay according to
[6, 17]. Briefly, the G quadruplex forming semaphorin 3F mRNA (S3F-sh) fragment was
labeled by the highly fluorescent purine analog 2-aminopurine (2-AP) at position 8,
producing S3F-sh_8AP (Dharmacon, Inc) (Figs 11, 12) [17]. The replacement of adenine
with 2-aminopurine has been shown to not disrupt G quadruplex formation and binding
interactions of various mRNAs with the RGG box peptide [4, 6, 17]. The fluorescence
spectroscopy experiments were performed on a J.Y. Horiba Fluoromax-3 equipped with a
variable temperature control in the sample chamber and a 3 mm path-length quartz
cuvette (Starna Cells) in a 150 μL final volume. The excitation wavelength was set at
310 nm and the emission spectrum was recorded in the range of 330-450 nm with a
bandpass of 5 mm for both the excitation and emission monochromators.
The binding was measured by titrating either FMRP ISO1, ISO2 or ISO3 into a
fixed concentration of 150 nM S3F-sh_8AP mRNA (in 10 mM cacodylic acid, pH 6.5,
150 mM KCl) at 25 °C. The samples were incubated for 10 min after each addition of
each increment of the respective FMRP isoform. The binding dissociation constant, K d ,
was determined by plotting the normalized S3F-sh_8AP mRNA steady state fluorescence
intensity at 371 nm as a function of the respective FMRP isoform concentration and
fitting

the

resultant

binding
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[17]:
(1)

where I B and I F are the steady state fluorescence intensity of the bound and free S3Fsh_8AP mRNA, [RNA] t is the total concentration of S3F-sh_8AP mRNA, and [P] t is the
total respective FMRP isoform concentration. The best-fit curve and subsequent K d and
R2 values for the respective FMRP isoform binding S3F-sh_8AP mRNA were generated
using Origin 7.0 (Fig 13). The experiments were repeated in triplicate and bovine serum
albumin (BSA) was also similarly titrated as a negative control (Fig 13A).

2.9

Secondary Structure Predictions of FMRP ISO1, ISO2 and ISO3
The amino acid sequence of each FMRP isoform was input for secondary

structure prediction using Porter, nnPredict, Jnet, and ProteinPredict computational
servers (Fig 14) [69-73].

2.10 Production of the Luciferase Reporter Gene Assay Plasmid Construct
The luciferase assay reporter construct was designed based on [26].

The

following DNA sequence was cloned into the multiple cloning site of the pUC18 plasmid
by GenScript: minimal T7 RNA polymerase promoter (25 bases), followed downstream
by the DNA sequence encoding the microtubule associated protein 1B (MAP1B) mRNA
5’-UTR mRNA sequence shown to form the G quadruplex structure (34 bases), followed
downstream by a portion of the luciferase 5’-UTR that immediately precedes the
luciferase gene (luc) start codon (18 bases), and then luc (Fig 15). The distance between
the end of the T7 promoter and the luc start codon was required to be less than 100 bases
in order to ensure expression of luciferase. In addition, an EcoRI restriction digest site
was incorporated immediately following the stop codon of luc to allow linearization of
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the plasmid prior to in vitro transcription. The pRM10 plasmid encodes mRNA with the
MAP1B mRNA G quadruplex sequence in its 5’-UTR, while pRM11 encodes a mutated
MAP1B mRNA G quadruplex sequence incapable of forming the G quadruplex structure
(Fig 15). The pRM12 plasmid does not contain any portion of the MAP1B sequence (Fig
15).

2.11 Purification and EcoRI Digest of the pRM10, prM11 and pRM12 Plasmids
The pRM10, pRM11 and pRM12 plasmids were transformed into and cultured
using BL21 Gold E. coli cells for the replication of the plasmids. The cells were cultured
at 37 °C, 250 rpm in LB + 200 μg/mL Amp and then mixed 1:1 with ultra-pure glycerol
and frozen at -80 °C. Cell were spread onto an LB + Amp agar plate using 4-way spread
technique and incubated 12 h at 37 °C. Single colonies were picked and cultured in 250
mL LB + Amp media in a sterile 1 L Erlenmeyer flask at 37 °C, 250 rpm, 12 h. The
respective pRM plasmid was purified using the E.Z.N.A. Endo-Free Plasmid Maxi Kit
(Omega Bio-Tek). The manufacturer’s Spin Protocol was employed, and the respective
plasmid was eluted using 2.25 mL of Endo-Free Elution Buffer and analyzed for purity
by 1% agarose gel electrophoresis and visualized by ethidium bromide stain (Fig 16).
The typical yield was 150 μg/mL and purified plasmids were stored at -20 °C.
The respective purified plasmid DNA was thawed on ice during preparation for
the EcoRI restriction enzyme digest. The restriction digest mixture was prepared in a 500
μL Eppendorf tube and contained 42 μL of ~150 μg/mL respective pRM plasmid, 5 μL
10x EcoRI NEBuffer (New England Biolabs), and 3 μL EcoRI restriction enzyme
solution (New England Biolabs). The restriction digest mixture was incubated at 37 °C,
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3.5 h using the MJ Mini Personal Thermocycler (Bio-Rad) and successful restriction
digest was analyzed by 1% agarose gel electrophoresis and visualized by ethidium
bromide stain (Fig 16).

2.12 Ethanol Precipitation Purification of the EcoRI Digested pRM plasmids
The reaction digest mixture was transferred to a 1.5 mL Eppendorf tube. The
respective digested pRM plasmid was purified by ethanol precipitation by adding 1/20th
volume of 0.5 M EDTA, 1/10th volume 3 M sodium acetate, and then 2 volume of icecold absolute ethanol. After addition of ethanol, the mixture was incubated at -20 °C for
30 min then centrifuged at 13,000 g for 15 min to pellet the respective digested plasmid.
The supernatant was decanted, and the pellet was centrifuged at 13,000 g for 1 min. The
remaining liquid was removed by a fine-tipped pipette set at a 10 μL volume. The
respective digested pRM plasmid was resuspended in TE buffer (10 mM Tris, pH 8.0, 1
mM EDTA) to a final concentration of 1 μg/mL (typically requiring ~150 uL TE) and
analyzed by 1% agarose gel electrophoresis for successful purification and visualized by
ethidium bromide stain (Fig 16).

2.13 In vitro Transcription of the pRM Plasmids and Purification of the Resultant
pRM mRNA Transcripts
The in vitro transcription of the respective restriction digested ethanol precipitated
pRM plasmid was performed according to the manufacturer protocol using the mMessage
mMachine T7 Kit (Ambion). The in vitro transcription reaction mixture was assembled
according to the manufacturer instructions, except 1 μg of respective restriction digested
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ethanol precipitated pRM plasmid template was used and the incubation occurred for 2.5
h at 37 °C. Following in vitro synthesis of the respective pRM transcript, TURBO
DNase was added to the reaction mixture and the reaction was incubated for 25 min at 37
°C. The respective pRM mRNA was purified by ethanol precipitation as described in
section 2.12 of the Materials and Methods, and the respective mRNA precipitated pellet
was resuspended in 50 μL TE buffer and KCl was added to 10 mM from a 4 M stock.
The effectiveness of the in vitro transcription reaction and mRNA purification were
assessed by 1% agarose gel electrophoresis and visualized by ethidium bromide stain (Fig
16).

2.14 In vitro Translation of the Respective pRM mRNA Transcripts
The in vitro translation of the respective purified pRM transcript was performed
according to the manufacturer’s protocol using the Rabbit Reticulocyte Lysate System
(Promega). The protocol calls for an annealing step for the mRNA at 60 °C prior to in
vitro translation to unfold any potential mRNA secondary structures. Hence, before their
addition to the translation reaction, the pRM plasmids were incubated in the presence of
10 mM KCl for 3 min to allow the folding of the mRNA into the G quadruplex structure
upon cooling. The amino acid mixture minus leucine, the amino acid mixture minus
methionine, and the RNasin ribonuclease inhibitor were added according to the
manufacturer’s protocol (Promega), and nuclease-free water was added to adjust the final
volume to 50 μL.

An aliquot containing the respective mRNA was added to a

corresponding aliquot of FMRP ISO1 such that the ratios of FMRP:pRM mRNA were
2:1, 1:1 and 0:1 and incubated at 25 °C for 20 min. The various respective FMRP
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isoform titration aliquots were diluted as needed in such a way that the volume of every
aliquot was identical to avoid the effects of dilution on luminescence emission. The entire
FMRP ISO1-pRM mRNA mixture was added to the in vitro translation reaction mixture.
Identical aliquots of the RRL were added to each reaction, followed by incubation at 30
°C for 1.5 h.
The luminescence emission intensity was measured at 560 nm using a Veritas
Microplate Luminometer (Turner Biosystems). The 4.5 μL room-temperature aliquots of
the respective RRL in vitro translation reactions were added to an opaque 96-well plate,
and the auto-injections system of the instrument delivered 90 μL of room temperature
luciferase assay reagent (Promega) to each well. The in vitro translated luciferase in the
RRL was incubated with the luciferase assay reagent for 10 sec prior to analysis of
luminescence emission intensity. The luminescence emission intensity was normalized
relative to that from the positive control pRM12 construct.
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CHAPTER 3: RESULTS AND DISCUSSION – RECOMBINANT EXPRESSION IN E. COLI,
PURIFICATION AND DIALYSIS OF FMRP ISOFORMS 1, 2 AND 3

3.1

Expression and Purification of Recombinant FMRP ISO1
Since the discovery of the FMR1 gene, the recombinant expression of FMRP in

E. coli has been continuously pursued, however the results of these efforts have been less
than satisfactory. Those who have attempted recombinant expression in E. coli have
experienced problems involving low levels of FMRP expression and yield as well as
protein precipitation [10, 28, 29, 45, 57, 59-63, 74]. In trying to circumvent these
problems, other studies have employed eukaryotic cell lines and in vitro transcription and
translation systems, but they also had limited success [13, 35, 43, 56-59, 61-64, 74].
Furthermore, FMRP is known to undergo phosphorylation and arginine methylation, and
such posttranslational modifications are likely concomitant when using eukaryotic and in
vitro systems of expression, as the enzymes involved in these modification pathways are
present in such systems [9, 10, 34-41]. Thus, to elucidate the explicit effects of these
posttranslational modifications on FMRP activity, both individually and simultaneously,
the expression of FMRP in the prokaryotic E. coli is vital.
Initially we attempted the FMRP ISO1 expression using the BL21 Gold (DE3) E.
coli cell line; however these experiments were not successful due to the low expression of
the protein. One cause for this poor FMRP ISO1 expression could have been codon bias.
The expression of FMRP ISO1 was then carried out using the Rosetta2 (DE3) pLysS E.
coli cell line. There exists seven transfer RNAs (tRNAs) that are not normally expressed
in E. coli, hence those seven codons are not recognized during translation. The Rosetta2
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(DE3) pLysS cell line contains the pRARE2 plasmid, encoding those seven tRNAs.
Analysis of the FMR1 sequence revealed that codon bias would have to be overcome.
This was of particular concern since of the seven compensated tRNAs, three correspond
to arginine codons and one corresponds to glycine and the RNA binding domain of
interest in the studies, the RGG box domain, is rich in arginine and glycine (Fig 2B).
Moreover, the three arginine codons appear a combined total of 35 times and the glycine
codon appears 25 times. In addition to compensating for codon bias, the utilization of the
pLysS cell line allows the cells to endogenously express lysozyme, eliminating the need
to add exogenous lysozyme and reducing the time necessary for the protein purification
procedure. Based on the tendency for FMRP to precipitate, the endogenous lysozyme
also enables a gentler lysis of the cells during the purification.
The transformed cells were grown at 37 °C until OD 600 was 0.8-1.0 and following
induction with IPTG, the cultures were grown for an additional 12 h at 25 °C. Following
cell harvesting and lysis, Ni2+ affinity chromatography was employed for the purification
process. Initially, the eluted fractions contained other protein impurities, which we
attempted to remove using additional steps, such as, but not limited to, gel filtration
chromatography, NH 4 SO 4 precipitation, or different Ni2+ affinity resin, however these
resulted in either protein loss or minimal increase in purity. By varying the buffer
components, imidazole concentration and pH during the optimization of the lysis and
wash steps of the Ni2+ affinity chromatography, pure FMRP ISO1 was successfully
produced using only the Ni-NTA resin column (Fig 7). Utilizing single-column affinity
chromatography reduces the necessary amount of time for purification, allowing analyses
of FMRP sooner, and decreases the quantity of steps that could be required, all of which
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Figure 7. 10% tris-glycine SDS-PAGE analysis of FMRP ISO1 purity after the Ni-NTA
affinity chromatography developed herein. FMRP ISO1 is not expressed strongly enough
in the presence of IPTG to be visibly distinguished from other protein bands in the cleared
crude supernatant hence that sample is not shown. Lane 1: EZ-Run protein marker
(Fisher Scientific). Lanes 2-8: eluted pure FMRP ISO1 fractions 4-10, respectively.
Visualized by Coomassie blue stain.

reduce the chance of protein precipitation. Furthermore, these studies revealed that the
long term storage of FMRP ISO1 is optimal at 4 °C in the presence of the elution buffer
containing 500 mM imidazole, 5% glycerol, and 1 mM EDTA. Glycerol has been shown
to stabilize proteins, and is routinely in many situations, such as protein refolding or
crystallization [75]. Although not well understood, it has been proposed that glycerol
induces protein compaction, reduces protein flexibility, stabilizes partially unfolded
intermediates, and affects both native and non-native protein aggregation. In addition, it
was shown that imidazole exhibits chaperone-like activity by enhancing green fluorescent
protein refolding and by suppressing heat-induced green fluorescent protein aggregation
[76]. It was proposed that imidazole binds to and blocks the exposure of nonnative
solvent-exposed hydrophobic surfaces of protein folding intermediates, possibly by
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imidazole binding solvent-exposed aromatic amino acid residues through stacking
interactions.

3.2

Mass Spectrometry Confirmation of FMRP ISO1 Expression
Upon obtaining pure FMRP ISO1, MALDI-TOF-MS analysis was one of the two

methods used to confirm successful FMRP ISO1 expression and purification. Pure
FMRP ISO1 from a 10% SDS-PAGE gel was excised, trypsin digested and MALDITOF-MS analyzed at the Genomics and Proteomics Core Laboratories at the University
of Pittsburgh. The five peptide fragments detected were identical to FMRP based on
matches within the Xcalibur mass spectrometry database (Table 1). The five fragments
detected are characteristic of several FMRP isoforms, hence based on these results
combined with the DNA sequencing of the pET21a-FMRP plasmid and the correct
molecular weight of expressed FMRP ISO1 was successfully expressed.

Table 1. Results from the MALDI-TOF-MS sequence analysis of trypsin digested FMRP ISO1
Peptide

Observed

Expected

Sequence

Mass

Mass

Δ Mass

Identified

(K)LIQEIVDK(S)

958.13403

958.1400

-0.00597

FMRP

(K)NVPQEEEIM*PPNSLPSNNSR(V)

2269.43498

2269.4425

-0.00752

FMRP

(R)VLVASSVVAGESQKPELK(A)

1842.12671

1842.1375

-0.01079

FMRP

(R)EDLM*GLAIGTHGANIQQAR(K)

2012.23703

2012.2433

-0.00627

FMRP

(K)AWQGM*VPFVFVGTK(D)

1583.87812

1583.8837

-0.00558

FMRP

* indicates oxidized methionine
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Protein

3.3 Concentration and Dialysis of Recombinant FMRP ISO1
The dialysis tubing concentration method was adapted for the concentration of
FMRP ISO1 [66]. This method drastically reduced the FMRP ISO1 precipitation and
loss due to membrane adsorption found when attempting other concentration methods,
such as lyophilization, NH 4 SO 4 precipitation, and centrifugal concentration filter devices
with regenerated cellulose or polyethersulfone membranes. In addition, the optimization
of the process revealed that concentration of ISO1 in the presence of hydrogen bondingcapable agents, such as glycerol and imidazole, inhibited precipitation [75, 76]. Based on
this, FMRP ISO1 was concentrated while in the elution buffer containing 500 mM
imidazole and 1 mM EDTA.
As previously stated, the presence of hydrogen bonding-capable agents, such as
imidazole and EDTA, reduced FMRP ISO1 precipitation.

The concentration of

imidazole to this point is 500 mM, too high to accurately represent in vivo conditions, yet
the presence of imidazole reduces FMRP ISO1 loss.

Additionally, the presence of

imidazole is not compatible with the fluorescence spectroscopy mRNA binding assay
because imidazole absorbs at 280 nm and the excitation of the 2-AP label occurs at 310
nm. Hence, the dialysis conditions herein were developed for the gradual removal of
imidazole which resulted in minimal loss through precipitation.

Initially, the

concentrated FMRP ISO1 is in elution buffer containing 500 mM imidazole, 5% glycerol
and 1 mM EDTA. Every dialysis step was performed at 4 °C for 12 h with 2 L of buffer
that contained 10 mM HEPES, pH 7.5, 300 mM LiCl, 5 mM β-mercaptoethanol, 5%
glycerol, 1 mM EDTA and varying concentrations of imidazole. The approximate 3 mL
concentrated FMRP ISO1, in elution buffer with 500 mM imidazole and 1 mM EDTA,
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was transferred to a dialysis buffer containing 200 mM imidazole, followed by 100 mM
imidazole, then 50 mM imidazole and zero imidazole. Following concentration and
imidazole removal, analysis by SDS-PAGE shows that FMRP ISO1 remains pure and
free of proteolytic degradation (Fig 8). After purification and dialysis, the concentration
of FMRP ISO1 was typically 50 μM in a volume of approximately 3 mL.

1

2

116 kDa
ISO1
66 kDa
45 kDa
35 kDa
25 kDa
18 kDa
14 kDa
Figure 8. 10% tris-glycine analysis of FMRP ISO1 after the purification, concentration and
dialysis processes and ready for binding analysis with G quadruplex mRNAs. Lane 1: EZRun protein marker. Lane 2: dialyzed FMRP ISO1. Visualized by Coomassie blue stain.

3.4

Recombinant Expression and Purification of FMRP ISO2 and ISO3
The naturally occurring splice acceptor sites at exon 15 result in the three longest

FMRP isoforms, with ISO1 being truncated by 13 residues to form ISO2, and truncated
an additional 12 residues to form ISO3 (Fig 5) [27-30]. The plasmids encoding for
FMRP ISO2 and ISO3 were prepared by GenScript, starting from the plasmid encoding
for FMRP ISO1. The successful deletion of the sequences of FMR1 to yield FMRP ISO2
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and ISO3 was confirmed by XhoI restriction enzyme digest and 1% agarose gel
electrophoresis (Fig 9). The two XhoI cut sites appear on each side of the region
encoding the RGG box and the FMR1 truncation sites, resulting in a relatively small
fragment by which the small quantity of bases deleted (39 total for ISO2 and 75 total for
ISO3) whose elimination could be detected on an agarose gel. The genetic deletions
were also verified by sequencing the coding region of the respective plasmids.

1

2

3

Figure 9. 1% agarose gel electrophoresis of XhoI digested pET-21a plasmids containing
the genes encoding FMRP ISO2 and ISO3. Lane 1: DNA marker. Lane 2: ISO2 encoding
plasmid. Lane 3: ISO3 encoding plasmid. The size difference resulting from gene
truncation is reflected in the migration distance and enhanced by the white underline.
Visualized by ethidium bromide.

The truncations of FMRP ISO1 of 12 and 25 residues to form ISO2 and ISO3,
respectively, did not alter the properties of the protein such that the protocol developed
for the production of ISO1 could not be applied to ISO2 and ISO3. Hence, pure FMRP
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ISO2 and ISO3 were expressed and dialyzed by following the protocol described above
for the recombinant expression and purification of FMRP ISO1 (Fig 10).

1

2

3

4

116 kDa

66 kDa

45 kDa
Figure 10. 10% SDS-PAGE analysis of the truncation to FMRP ISO1 to form ISO2 and
ISO3. Analysis occurred post-dialysis. Lane 1: EZ-Run protein marker. Lanes 2-4: FMRP
ISO1, ISO2 and ISO3, respectively. The size differences resulting from FMRP truncations
are reflected in the migration distance and enhanced by the blue underline. Visualized by
Coomassie blue stain.
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CHAPTER 4: RESULTS AND DISCUSSION – QUANTITATIVE ANALYSIS OF BINDING
ACTIVITY OF FMRP ISOFORMS 1, 2 AND 3 TO IN VIVO NEURONAL TARGET G
QUADRUPLEX FORMING MRNA

4.1

FMRP ISO1, ISO2 and ISO3 Binding Activity to G quadruplex Forming

mRNA
To confirm that the recombinant FMRP ISO1 retained activity throughout the
developed protocol herein for binding G quadruplex forming mRNA, its ability to bind G
quadruplex mRNA was evaluated using fluorescence spectroscopy [4, 6, 16, 17, 45].
Depending on the particular RNA sequence, the formation of the G quadruplex
structure requires K+ ions in different concentrations. Based on the variability of the
required K+ concentration, the binding assay buffer must have K+ concentration
flexibility; hence the FMRP isoforms must be in a buffer devoid of K+. Moreover, the G
quadruplex can form in the presence of Na+ ions but this is thermodynamically less stable
relative to when K+ is present [18]. Thus, Li+ was employed throughout the purification
and dialysis processes in place of the routinely used K+ and Na+ buffer counterions.
The mRNA we employed (S3F-sh_8AP) in the respective FMRP fluorescence
spectroscopy binding assay was derived from the semaphorin 3F mRNA, which encodes
for the Sema 3F protein (Fig 11) [17]. The Sema 3F protein is expressed in cerebellar
granule cells and plays an important role in brain development by functioning as a chemo
repellant to axon extension, neuronal migration and growth cone guidance [49, 50].
Previous studies have shown that the S3F mRNA is an in vivo neuronal binding target of
FMRP and that, in vitro, S3F-sh_8AP mRNA folds into a G quadruplex structure which
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5’-GAUUGGAAGGGAGGGAGGUG-3’

Figure 11. Left figure shows the proposed G quadruplex structure of S3F-sh_8AP mRNA
with the location of the 2-aminopurine fluorescent label in red [17]. Right figure shows the
sequence of S3F-sh_8AP mRNA with the 2-aminopurine fluorescent label in red and the
guanine bases involved in G quadruplex formation underlined. The adenine analog 2aminopurine was substituted for a naturally occurring adenine in the sequence.

is bound with high affinity and specificity by a synthetic FMRP RGG box peptide (Fig 5)
[6, 17, 45, 77]. S3F-sh_8AP mRNA was labeled at position 8 by the highly fluorescent
adenine analog 2-AP (Fig 12). This adenine analog was substituted for a naturally
occurring adenine in the S3F mRNA, and 2-AP has been shown to be non-perturbing to
both the folding of the G quadruplex mRNA structure and binding by the synthetic RGG
box peptide [4, 6, 17]. The fluorescence emission of 2-AP is sensitive to changes in its
local microenvironment (Fig 12), such as stacking on other bases and protein binding
[78]. Increasing amounts of a respective FMRP isoform were titrated against a fixed
concentration of the labeled mRNA (150 nM), monitoring the steady-state fluorescence
changes of the 2-AP reporter at 371 nm (Fig 13). By fitting the respective resultant
binding curves with Equation 1 (Materials and Methods) using Origin software, the
binding dissociation constants (K d ) for the respective FMRP isoform were determined
(Fig 13) (Table 2). These dissociation constants are in the nM range, being comparable,
but not identical, to the value previously reported for the binding of the synthetic FMRP
36

A

B

2-Aminopurine

C

Adenine

Figure 12. (A) Molecular structure of the adenine analog fluorescent label 2-aminopurine.
(B) Molecular structure of adenine. (C) Changes in the 2-aminopurine fluorescence
emission intensity from changes in its local microenvironment.

RGG box peptide to this mRNA (Fig 5) (Table 2) [17]. Additionally, the K d values of
FMRP ISO1, ISO2 and ISO3 for the G quadruplex forming S3F-sh_8AP mRNA are also
in the same range with the K d of the synthetic FMRP RGG box peptide for the G
quadruplex forming MAP1B_19AP mRNA, at 20.1 ± 6.4 nM [4]. As a negative binding
control, BSA was titrated into S3F-sh_8AP mRNA resulting in a minimal change (less
than 10%) of the steady-state fluorescence of the 2-AP reporter (Fig 12A).

Table 2. Results of the fluorescence binding
assays of various FMRP isoforms to G quadruplex
forming S3F-sh_8AP mRNA
FMRP Isoform
K d (nM)
R2
ISO1
104 ± 11
0.995
ISO2
46 ± 4
0.996
ISO3
25 ± 3
0.991
RGG box peptide
1.0 ± 0.4
-
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Figure 13. (A) (■) Best-fit curve from the steady-state fluorescence spectroscopy emission
of S3F-sh_8AP mRNA at 371 nm as ISO1 is titrated and binding. The result was a Kd of
104.1 ± 10.9 nM and R2 value of 0.995. (▲) The negative binding control from the steadystate fluorescence spectroscopy emission of S3F-sh_8AP mRNA at 371 nm as BSA is
titrated. (B) Best-fit curve of S3F-sh_8AP mRNA at 371 nm as ISO2 is titrated and binding.
The result was a Kd of 45.7 ± 4.1 nM and R2 value of 0.996. (C) Best-fit curve of S3Fsh_8AP mRNA at 371 nm as ISO3 is titrated and binding. The result was a Kd of 24.7 ± 3.3
nM and R2 value of 0.991.
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4.2

Analysis of the Effects of FMRP Truncations via Alternative Splicing on the

Binding Activity to G quadruplex Forming mRNA
Efforts have not yet yielded a structure for any FMRP isoform; additionally, there
are no known structures for any RGG box domain-containing protein. Moreover, the
RGG box domain and surrounding region are thought to be unstructured, and it is thought
that the RGG box becomes structured during the binding event with the G quadruplex
mRNA [47]. The three longest FMRP isoforms studied here are products of the three
alternative splice acceptor sites at exon 15, and these alternative splice products are the
result of truncations that occur in close proximity to the RGG box domain (Fig 5) [2730]. Our fluorescence spectroscopy binding experiments indicate that as FMRP ISO1 is
truncated by 13 residues to form ISO2, and then another 12 residues to form ISO3, the
binding affinity of the FMRP RGG box domain for G quadruplex mRNA increases
(Table 2).
In effort to elucidate the rationale for the righter K d as FMRP truncation occur,
we performed secondary structure predictions for FMRP ISO1, ISO2 and ISO3 (Fig 14)
[69-73]. Of the four secondary structure predictions utilized, at least two had to agree in
order to be considered valid for these studies, according to the predictions from the
Porter, nnPredict, Jnet, and ProteinPredict computational servers (Fig 14) [69-73]
According to the predictions, the RGG box domain and surrounding region are
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40
α-helix 2

α-helix 3

Figure 14. Secondary structure predictions of the regions surrounding the RGG box domain and the effects of the naturally occurring
alternative splice acceptor sites at exon 15 truncating FMRP ISO1 to form ISO2 and ISO3 on the proximity of the predicted α-helical
regions. The three regions predicted to be structured are α-helices and described above. The 13 residue sequence truncation of ISO1 to
form ISO2 is in blue bold. The sites of posttranslational phosphorylation housed in this sequence are indicated by double daggers (‡). The
additional 12 residues sequence truncation to form ISO3 is in red bold. The RGG box domain is in black bold with the RGG repeats of the
domain underlined. The sites of posttranslational methylation are indicated by arrows (↓). The truncations that occur to ISO1 to form ISO2
and ISO3 do not disrupt the regions predicted to be α-helices. The truncations bring α-helix 1 and α-helix 2 into closer proximity with one
another, but do not affect the distance between α-helix 2 and α-helix 3.

α-helix 1

↓
↓
↓ ↓
PPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTD

ISO3

↓
↓
↓ ↓
PPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTD

ISO2

‡ ‡
‡
↓
↓
↓ ↓
PPNRTDKEKSYVTDDGQGMGRGSRPYRNRGHGRRGPGYTSGTNSEASNASETESDHRDELSDWSLAPTEEERESFLRRGDGRRRGGGGRGQGGRGRGGGFKGNDDHSRTDNRPRNPREAKGRTTD

ISO1

predominately unstructured, with a short five residue predicted α-helical sequence (αhelix 2) between two other predicted α-helices (α-helix 1, α-helix 3). The three predicted
α-helices are present in all three FMRP isoforms, and it is noteworthy that α-helix 2 is
comprised by five of the 10 residues between the sequence eliminated to form ISO3 and
the RGG box domain. The distance of the unstructured region between α-helix 2 and αhelix 3 for all three FMRP isoforms is 42 residues, and contains the RGG box domain.
The unstructured region between helices 1 and 2 is shortened as ISO1 is truncated to
form ISO2, and further again to form ISO3. This separation is 59, 46 or 34 residues, for
ISO1, ISO2 or ISO3 respectively, bringing the predicated helix 1 and helix 2 into closer
proximity. Additionally, the segments of FMRP truncated when forming ISO2 and ISO3
are predicted to be unstructured. A possible explanation for the increase in binding
affinity to G quadruplex mRNA as FMRP is truncated is that the truncations bring helix 1
and helix 2 closer to one another, and as a result helix 3 is also brought closer to helix 1.
This would likely cause this region of FMRP to become more structured in general.
Considering it is thought that the RGG box domain is unstructured and becomes
structured upon binding substrate G quadruplex mRNA, it is possible that increasing the
general level of structure for this region containing the RGG box domain will result in the
RGG box domain having a better conformation and orientation in space for binding the G
quadruplex mRNA to yield a higher probability for a more productive binding event, thus
increasing binding affinity as FMRP truncations occur.
The identity of the residues deleted during the alternative splice truncation events
could also offer an explanation for the increasingly tighter binding affinity as ISO1 is
truncated to form ISO2 and then ISO3 (Figs 5, 13) (Table 2). The sequence deleted to
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form ISO2 contains three glutamate residues and no other charged residues, hence giving
this 13mer a 3- overall charge.

In addition, the three sites of serine phosphorylation

reside in this 13mer, which would increase its negative charge to 9-. The 12mer deleted
to form ISO3 from ISO2 contains three aspartate residues and a glutamate residue,
combined for a 4- charge. However, this 12mer also contains a histidine residue and an
arginine residue, resulting in an overall 2- charge for this 12mer. Combining the 13mer
truncated to form ISO2 and the 12mer truncated to form ISO3, the net charge for the
overall truncated segment is 5-. Moreover, if the three serine residues, only present in
ISO1, are posttranslationally phosphorylated, the net charge for the overall truncated
segment becomes 11-. Based on the high negative charge character of this region of
FMRP, repulsion against the phosphate backbone of the mRNA might occur.
It has been reported that increased FMRP ISO1 binding to FMRP mRNA,
containing a guanine-rich sequence in the coding region that potentially forms a G
quadruplex structure, decreases the synthesis of FMRP ISO1, and increases the synthesis
of FMRP ISO2 and ISO3 [44]. Hence, binding of ISO1, containing the region shown to
be posttranslationally phosphorylated, to FMRP mRNA results in the increased synthesis
of ISO2 and ISO3, both of which lack the sites of phosphorylation. It is unclear whether
the mRNA corresponding to ISO2 and ISO3 are present on the polyribosomes, or if the
binding of FMRP ISO1 protein to FMRP ISO1 mRNA triggers an alternative splicing
event at the polyribosome followed by translation to form ISO2 and ISO3. Moreover,
FMRP ISO3 has been shown to be considerable less methylated on the RGG box domain
arginines than ISO1 and ISO2 [41]. Given that FMRP is methylated within its RGG box
domain, it stands to reason that this posttranslational modification would reduce its
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binding affinity for G quadruplex mRNA. Additionally, our results indicate that FMRP
ISO3 has a tighter binding for G quadruplex mRNA than ISO2, which in turn binds
tighter than ISO1, when all three isoforms are devoid of posttranslational modifications
(Fig 13) (Table 2). Thus, one could envision a model according to which the binding of
FMRP ISO1 to FMRP mRNA results in the production of FMRP ISO2 and ISO3, which
bind with much higher affinity to other G quadruplex mRNA targets and, at least in the
case of ISO3, are resistant to methylation of their RGG box domain arginines, preserving
their tight G quadruplex mRNA binding. Therefore, increased binding of ISO1 to FMRP
mRNA causes an increase in ISO2 and, more importantly, ISO3 expression, which then
enables the cells to increase the tightness in binding and regulating the expression of G
quadruplex mRNAs.

These events of alternative splicing and posttranslational

modifications are clearly mechanisms of FMRP regulation utilized by cells. Further
investigation is needed of the individual and combined effects of these events as well as
when the cells utilize which events under what cellular conditions and circumstances.
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CHAPTER 5: RESULTS AND DISCUSSION – ANALYSIS OF THE TRANSLATION
REGULATION ACTIVITY OF FMRP ISOFORMS 1, 2 AND 3 FOR A REPORTER GENE WITH
A G QUADRUPLEX STRUCTURE IN THE 5’-UTR

5.1

The Luciferase Reporter Gene Constructs pRM10, pRM11 and pRM12
FMRP has demonstrated mRNA translation regulation activity and binding

activity to G quadruplex mRNA [4, 6, 8, 17]. Bioinformatics analysis has revealed that
potentially 2334 G quadruplex structures could fold in the 5’-UTR of human mRNA
transcripts from known protein-coding genes. Evidence supporting the involvement of G
quadruplex mRNA structures in posttranscriptional regulation of gene expression was
provided by individually introducing the known G quadruplexes from the 5’-UTRs of
two different mRNAs into the mRNA 5’-UTR of a reporter gene and observing that the
reporter gene translation was inhibited [25, 26].

Similar results occurred when the

proposed G quadruplex forming sequence from the coding region of FMRP mRNA was
inserted into the 5’-UTR of a reporter gene [79].
The model developed by Menon et al for FMRP translation regulation proposes
that as the local concentration of FMRP relative to G quadruplex mRNA increases, the
protein unwinds the G quadruplex structure (Figs 1, 6) [4, 8], allowing for the translation
of the target mRNA to occur. To test the ability of the three FMRP isoforms to regulate
translation, we have designed a plasmid, pRM10, which contains the G quadruplex
sequence from the 5’-UTR of MAP1B mRNA inserted in the 5’-UTR of the firefly
luciferase reporter gene (Fig 15). As positive controls, the pRM11 plasmid, with four
guanines mutated to cytosine, hence abolishing the G quadruplex structure, and the
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pRM10
mRNA

pRM11
mRNA

GGGAGAGGGCGGAGGGGGAGG Luciferase 5’ UTR Luciferase
5’ cap

MAP1B
G quadruplex UTR

GGGAGAGGGCGGACCCCGAGG Luciferase 5’ UTR Luciferase
5’ cap

Mutated MAP1B
G quadruplex UTR

pRM12
mRNA

Luciferase 5’-UTR Luciferase
Deleted MAP1B
G quadruplex UTR

5’ cap

Figure 15. Schematic of the pRM mRNAs utilized, corresponding to their respective
plasmids, for the luciferase reporter gene assay to analyze the activity of FMRP to
regulate the translation of mRNAs containing the G quadruplex structure and analyze the
changes in the FMRP translation regulation activity resulting from the alternative splice
truncations. All three pRM mRNAs contain identical sequences from the luciferase mRNA
5’-UTR. The pRM10 mRNA contains in its 5’-UTR the G quadruplex forming sequence
from the MAP1B mRNA 5’-UTR. The pRM11 plasmid is identical to pRM10 except four
guanine residues (bold red) were mutated to cytosines to abolish the G quadruplex
structure. The pRM12 mRNA contains no sequence from the MAP1B mRNA.

pRM12 plasmid, with no included MAP1B mRNA sequence, were designed (Fig 15).
All plasmid constructs were confirmed by DNA sequencing. The rationale behind these
experiments is that if the proposed model is correct, as more FMRP binds to the MAP1B
G quadruplex structure located in the 5’-UTR of the luciferase mRNA, the G quadruplex
structure will be unwound, allowing for the translation of the luciferase protein.
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5.2

Purification, Restriction Enzyme Digestion and in vitro Transcription of

pRM10, pRM11 and pRM12 Plasmids
The respective pRM plasmids were purified from BL21 Gold E. coli cells,
resulting in a typical yield of 150 μg/mL (Fig 16). The purified pRM plasmids were
linearized near downstream of the luc stop codon via EcoRI restriction enzyme digestion
followed by ethanol precipitation purification (Fig 16). The respective linearized pRM
plasmids were transcribed in vitro to produce the corresponding respective pRM mRNAs
(Fig 16).

Transcribed pRM mRNAs were purified via ethanol precipitation in

preparation for the in vitro translation assay to analyze the translation regulation activity
of FMRP. The pRM10 mRNA was annealed in the presence of 10 mM K+ to allow the
formation of the G quadruplex structure.

The pRM11 and pRM12 mRNAs were

similarly annealed although they should not be able to form the G quadruplex structure.

5.3 Analysis of FMRP Translation Regulation Activity for a Reporter Gene
Containing a G quadruplex Structure in its mRNA 5’-UTR
It has been previously shown that the presence of a G quadruplex structure in the
mRNA 5’-UTR of a reporter gene reduces its translation [26]. Thus, just the presence of
the MAP1B G quadruplex structure in the 5’-UTR of the reporter gene mRNA, from
pRM10, even in the absence of FMRP ISO1 shows a 95.1% reduction in the luciferase
reporter translation relative to the translation of the positive control mRNA from pRM12
(Fig 17, brown bars). As FMRP ISO1 is titrated in at a 1:1 ratio, the in vitro translation
of pRM10 mRNA is further repressed to 99.8% relative to the translation of the
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pRM10 plasmid
DNA (4.8 kB)

5 kB
4 kB
2 kB
1.5 kB

pRM10 mRNA
(1.7 kB)

Figure 16. 1% agarose gel electrophoresis analysis of the pRM10 plasmid DNA and in
vitro transcribed mRNA throughout preparation for the in vitro translation reporter gene
assay. Lane 1: DNA marker. Lane 2: undigested pRM10 plasmid DNA. Lane 3: EcoRI
digested pRM10 plasmid DNA. Lane 4: ethanol precipitated EcoRI digested pRM plasmid
DNA. Lane 5: in vitro transcribed pRM10 mRNA.

positive control mRNA from pRM12 (Fig 17, red bars). This translation repression is in
agreement with the model proposed by Menon et al that when present at low levels,
FMRP stabilizes the G quadruplex structure present in the 5’-UTR of the luciferase
mRNA (Fig 6) [4]. As the concentration of titrated FMRP ISO1 increases to a 3:1 ratio,
the translation of pRM10 mRNA is further repressed to 100% relative to the translation
of the positive control mRNA from pRM12 (Fig 17, green bars). Upon titrating FMRP
ISO1 to an 8:1 ratio, the pRM10 mRNA translation remains repressed at 100% of the
positive control pRM12 mRNA (Fig 17, yellow bars). The luciferase translation results
using the pRM10 mRNA are not in full agreement with the proposed model for FMRP
translation regulation function (Fig 6). As shown previously using the synthetic RGG
box peptide, as the RGG box peptide concentration increases, the G quadruplex structure
unwinds [4, 6, 17]. According to the proposed model, as the mRNA G quadruplex
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structure unwinds, the mRNA becomes more available for translation. Our in vitro
translation results support this model when at low levels of FMRP ISO1 (1:1, 3:1), in that
the pRM10 translation is repressed (Fig 17). However, at high levels of FMRP ISO1
(8:1), the translation of pRM10 mRNA remains repressed, which does not support the
model since the G quadruplex structure was not unwound and translation of pRM10 was
not allowed to occur (Fig 17).

1.0

0:1 FMRP:mRNA
1:1 FMRP:mRNA
3:1 FMRP:mRNA
8:1 FMRP:mRNA

0.8

0.586

0.7
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1.62 x 10-3
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5.57 x 10-6

0.1

2.37 x 10-6
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5.13 x 10-3
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5.0 x 10-2

Luciferase Expression via Normalized
Luminescence Intensity (560 nm)

0.9

0.0

pRM10
mRNA

pRM11
mRNA

pRM12
mRNA

Figure 17. Normalized luminescence intensity, representing luciferase expression, from
the three pRM mRNA constructs as FMRP ISO1 is titrated.

The pRM12 reporter gene construct, containing no sequence originating from
MAP1B mRNA, has shown to be an effective positive control for luciferase expression
since the design of the construct and the presence or absence of FMRP ISO1 has had no
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effect on luciferase expression and translation (Figs 15, 17). However, the pRM11
reporter gene construct was not a good negative control. In the absence and presence of
FMRP ISO1, we expected the luciferase expression from the pRM11 mRNA to be
comparable to that from pRM12, but this was not observed (Figs 15, 17). Analysis of the
mutated MAP1B mRNA sequence inserted into the 5’-UTR of the pRM11 construct
mRNA indicates that it is possible that the number of guanines mutated to cytosine
residues might not have been sufficient to perturb the formation of a G quadruplex
structure (Fig 15). Sequence analysis reveals that 12 guanine residues remain from the
original MAP1B G quadruplex sequence, and considering that the G quartet structure
requires four guanine residues to form a G quadruplex structure, three sets of G quartets
stacked could still form a G quadruplex structure in the 5’-UTR of the pRM11 mRNA. It
is, however, likely that this G quadruplex structure formed by pRM11 mRNA is different
from that of pRM10 mRNA.

The potential for pRM11 mRNA to fold into a G

quadruplex structure is supported from the 41.4% reduction of luciferase translation, in
the absence of FMRP ISO1, relative to the pRM12 mRNA positive control. Further
support is provided by the increased translation repression, 90.7%, 99.5%, and 99.8%
reduction relative to control, when FMRP ISO1 is titrated to ratios of 1:1, 3:1, and 8:1,
respectively, with pRM11 mRNA. The normalization of the luminescence was relative to
that for the pRM12 construct for a respective FMRP ISO1 titration point. Additionally,
the differences in translation regulation activity between the three FMRP isoforms and
determination of the ability of FMRP ISO2 and ISO3 unwind the G quadruplex structure
need to be investigated.
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CHAPTER 6: CONCLUSIONS

6.1

Expression, Purification and Dialysis of FMRP ISO1, ISO2 and ISO3
The expression protocol of FMRP ISO1, ISO2 and ISO3 was successfully

developed and performed using the Rosetta 2(DE3) pLysS E. coli cell line. Expression of
the FMRP isoforms using E. coli is critical in that the expressed proteins are devoid of
the posttranslational modifications of phosphorylation and arginine methylation. This
enables the analysis of the direct effects of these posttranslational modifications,
individually and simultaneously, on the FMRP activity via its RGG box domain for the
binding of G quadruplex forming mRNAs as well as other processes in which FMRP has
been shown to be involved.
The conditions for the purification of the FMRP isoforms using a single Ni2+
affinity chromatography step was developed, reducing the time and processes necessary
for purifying the notoriously difficult FMRP.

In addition, the protocol for the

concentration of the FMRP isoforms was developed, considerably reducing the protein
loss from precipitation and membrane adsorption of previous methods.
To prepare the FMRP isoforms for analysis of binding activity for G quadruplex
forming mRNAs, the conditions for the dialysis of the FMRP isoforms to remove
imidazole were developed. The dialysis protocol developed herein results in the gradual
dialysis of the FMRP isoforms and minimizes protein loss through precipitation.
Additionally, the dialysis protocol is devoid of K+ and Na+ counterions. Various K+
concentrations are required depending on the G quadruplex mRNA structure that is used
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during assays; hence with the FMRP isoforms in a buffer devoid of K+ enables the
addition of a known K+ concentration as needed.

6.2

Analysis of the Differences in Binding Activity of FMRP ISO1, ISO2 and ISO3

for in vivo Neuronal Target G quadruplex Forming mRNA
Differences in the in vitro binding activity for in vivo neuronal target G
quadruplex mRNA between the three longest FMRP isoforms, formed via naturally
occurring alternative splicing, was shown from this study. The increase in binding
affinity for G quadruplex mRNA as FMRP ISO1 is truncated to form ISO2 and ISO3 was
shown herein, further supporting the postulation that alternative splicing serves a
mechanism for regulating FMRP activity. However, the rationale, at the molecular level,
for how these FMRP truncations result in tighter binding for G quadruplex forming
mRNA remains unclear.

6.3 Analysis of the Activity of FMRP ISO1 to Regulate Gene Expression by
Regulating Translation
The results do not fully agree with the model proposed by Menon et al for the
translation regulation function of FMRP. We have shown that low levels of FMRP
repress the translation of an mRNA that contains a G quadruplex structure in its 5’-UTR,
which is in agreement with our model. However, as the level of FMRP increases, the
level of reporter gene translation is further repressed, in contrast to the proposed model
for the mechanism by which FMRP exerts its translation regulation function.
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6.4

Future Research
The expression of FMRP ISO1, ISO2 and ISO3 using E. coli renders the protein

devoid of the posttranslational modifications of serine phosphorylation and arginine
methylation. The explicit effects of these modifications, individually and simultaneously,
on the binding activity for G quadruplex forming mRNA and translation regulation
activity for mRNAs that contain the G quadruplex structure need to be further
investigated. To further investigate the effects of alternative splicing on the activity of
FMRP, ISO2 and ISO3 need to be applied to the luciferase reporter translation regulation
activity assay. In addition, more guanines from the pRM11 construct need to be mutated
to assure complete abolishment of the G quadruplex structure for this construct.
Recently, a patient diagnosed with the FXS phenotype expressed normal levels of FMRP.
Genetic analysis showed that this patient had a guanine insertion that caused a frameshift
mutation between the RGG repeats of the RGG box domain, abolishing the second RGG
of the repeats, as well as a premature stop codon. The binding activity of this FMRP
mutant for G quadruplex forming mRNA and translation regulation activity for mRNAs
that contain the G quadruplex structure needs to be further investigated.
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